Korro Bio, Inc.
KRRO
Positions held
Your positionsKRRO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $155.80M | Enterprise value | $82.97M | Trailing P/E | — | Forward P/E | -2.39 |
| PEG | — | Price / book | 1.51 | Beta | 2.36 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -32.3% |
| Profit margin | 0.0% | ROE | -97.7% | ROA | -28.0% | Debt / equity | 0.41 |
| Current ratio | 9.55 | Free cash flow | -$41.39M | Analyst recommendation | strong_buy | Mean target | $20.20 |
| 52w high | $55.89 | 52w low | $5.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $1.3M | $1.1M | $1.5M | — |
| Op margin | — | — | -1229.3% | -1764.9% | -1778.7% | — |
| Net income | -$18.9M | -$19.6M | -$50.0M | -$18.1M | -$25.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.1M | -$20.4M | -$15.9M | -$19.2M | -$26.0M | — |
- Operating margin expanded to -1229.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0.0M | $0.0M |
| Op margin | -1366.4% | -4047.1% | — | — |
| Net income | -$117M | -$83.6M | -$81.2M | -$58.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$87.3M | -$91.9M | -$84.5M | -$59.0M |
Headlines — positive tone
• [OK · fundamentals] All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
News
2026-10-05 · Korro Bio Says First Participants Dosed in KRRO-121 Trial
2026-10-05 · Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
2026-09-11 · Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-27 · Korro to Participate in Upcoming Investor Conferences
2026-08-14 · Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-10 · All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
2026-08-06 · Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-27 · Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Price (daily)
Full chart · RSI · MACD · patterns